- Home
- BKKT vs ARCT Comparison
BKKT vs ARCT Comparison
Compare BKKT & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKKT | ARCT |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 360.6M | 293.9M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BKKT | ARCT |
|---|---|---|
| Price | $5.05 | $9.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $16.00 | ★ $23.80 |
| AVG Volume (30 Days) | ★ 1.1M | 627.1K |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ 1.95 | N/A |
| Revenue | ★ $2,335,243,000.00 | $82,031,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $64.21 |
| P/E Ratio | $2.67 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.13 | $5.50 |
| 52 Week High | $31.51 | $17.96 |
Technical Indicators
Market Signals| Indicator | BKKT | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 26.83 | 35.23 |
| Support Level | N/A | $6.53 |
| Resistance Level | $9.99 | $17.85 |
| Average True Range (ATR) | 0.39 | 1.01 |
| MACD | -0.16 | -0.27 |
| Stochastic Oscillator | 2.65 | 0.69 |
Price Performance
Historical ComparisonAbout BKKT Bakkt Holdings Inc.
Bakkt Inc builds digital financial infrastructure designed to support institutional participation in the digital asset economy. The company platform is built to accommodate various digital assets and offers its clients the flexibility to build a product that aligns with its vision and customers' needs. Its services include Bakkt Markets, Bakkt Agent, Bakkt Global.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.